Oncolytics Biotech Inc ONCY

Inflation Reduction Act (IRA) boosts biological drugs

[Noteable]

"This means that biologics will be less affected by the IRA compared to small molecule drug development, which in turn could impact decisions on biotech financing going forward....

... The IRA may impact revenues resulting in reduced investments in (in-house small molecule) R&D, but further biopharmaceutical collaborations may help to support future innovation by mitigating costs as interest rates continue to rise."

https://www.pharmaceutical-technology.com/comment/inflation-reduction-biologic-drug-venture/

[Noteable]

July 12, 2023 - A Mizhou Securities industry commentary from its recent healthcare banking panel noted that M&A strategy between large and small biotechnology/ pharmaceutical companies could be affected by the Inflation Reduction Act (IRA), in terms of price capping and patent life reductions. Under the IRA, biologics are granted a 13-year protection period before price controls come into

[Noteable]

July 11, 2023 - Increasing longevity and the resulting healthcare opportunity are seen as one of four unstoppable trends reshaping the world and transforming the ways we live and work, according to Julie Koo of Citi Global Wealth Investments. "Over the last few years, technological innovation has disrupted multiple sectors including healthcare. We’re seeing tremendous innovation in

[Noteable]

The legislation has already spurred some pharmaceutical companies to rearrange priorities and cut projects. In November 2022 Lilly cut a Fosun Pharma-partnered cancer med, citing the small molecule provisions. Astellas also teased potential future divestments that might occur due to the IRA at ASCO. Astellas' phase 3 trial of Xtandi (small molecule chemotherapy) and Leuprorelin

[Noteable]

ONCY's pelareorep is a "platform drug therapy" that can be used in multiple cancers, most currently in pancreatic, breast, anal, and colon cancer, with the potential of ovarian, glioblastoma and other GI cancers. With the passing of the IRA into law in 2022. biologics like ONCY's platform drug pelareorep will gain 13 years of FDA market exclusivity in each new indication

[Noteable]

March 06, 2024 - Forbes - " ..... “the small molecule penalty.” The IRA calls for price controls to be instituted after a drug has been on the market for either nine years for small molecule drugs (i.e. pills) or 13 years for biological drugs (injectables). This four-year difference is a big deal for a biopharma company, )since) the last years of sales for any drug are its most

[Noteable]

Michelle McMurry-Heath, MD, PhD, former president and CEO of the Biotechnology Innovation Organization (BIO), said that the Orphan Drug Act and breakthrough designation and accelerated approval have really given an advantage to diseases that target small patient populations with first-in-class treatments. McMurry-Heath also commented on AI’s role in improving precision in patient selection

[Noteable]

February 13, 2024 - Court Dismisses PhRMA Lawsuit Challenging IRA . "Today, the district court for the Western District of Texas granted the government’s motion to dismiss the lawsuit brought by PhRMA and other organizations challenging the Drug Price Negotiation Program of the Inflation Reduction Act.  The lawsuit was brought by three Plaintiffs: PhRMA, the Global Colon

[Noteable]

April 30, 2024 - A federal judge in New Jersey on Monday ruled that the drug price negotiations outlined in the Inflation Reduction Act is constitutional, rejecting the arguments put forth by J&J and BMS. This is the latest decision dismissing the unconstitutional claims of certain Big Pharma companies. Last month, a federal judge in Delaware ruled against AstraZeneca saying that the Medicare

[Noteable]

May 01, 2024 - Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court   Drug development had already been trending toward biologics. This drug class received 30% more VC funding in 2022 than small molecule candidates, noted John Stanford, executive director of life sciences venture capital coalition Incubate—but the gap jumped to 50% in 2023, and Stanford contends that

[Noteable]

May 08, 2024 - On April 29th, the district court for the district of New Jersey (J. Quraishi) granted summary judgment for the Government in two cases, brought by BMS and Janssen, challenging the IRA’s Drug Price Negotiation Program.  BMS and Janssen alleged that the Drug Price Negotiation Program (i) effects a taking of personal property without just compensation in

[Noteable]

The IRA negotiations do not apply to drugs with generic or biosimilar competition or for orphan drugs, which are used to treat a single disease. It also differentiates between small molecule drugs, like pills, which will be granted nine years of exclusivity before negotiations begin, and large molecule drugs, or complex biologics, which have 13 years of exclusivity. Currently, many drugs are

[Noteable]

mRNA vaccines are synthetically manufactured and although their biological mechanism of action and immune response are similar to biologics, they would appear to fall under the small molecule 9 years of exclusivity under the recently passed IRA. https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=36036952 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9012156/

[Noteable]

"The Wod is Getting Out !"

[Noteable]

Should read: " The Word is Getting Out !" - And you can only hear what has been said if you were actually listening.

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-ord-shs?postid=35922919 Also from the March 07, 2024 "State of Union" address the Biden administration is also looking to expand the $2,000 cap on out-of-pocket spending for prescription drugs, which will apply to senior beneficiaries of Medicare by 2025. This move will add further incentive to the use of biologics

[Noteable]

March 04, 2024 -  IRA Drives Pfizer’s Decision to Focus on Biologics, Not Small Molecules. By 2030, Pfizer expects biologics such as antibody-drug conjugates (ADCs) and bispecific antibodies to contribute approximately 65% of its oncology revenues—up from 6% in 2023, a more than 10-fold increase. At the same time, company leaders said that the mix of small molecule drugs in

[Noteable]

https://www.forbes.com/sites/joshuacohen/2023/10/02/inflation-reduction-act-may-curb-patent-practices-that-forestall-market-entry-of-biosimilars/?sh=63365c4f4e30

[Noteable]

March 08, 2024 - The IRA’s Medicare Drug Price Negotiation Program requires the U.S. Department of Health and Human Services (HHS) to negotiate “maximum fair prices” with drug manufacturers for certain brand-name, small molecule drugs covered under Medicare Part D. This allowance begins seven years after a drug’s approval; at nine years, the negotiated drug price kicks in. Gaining the FDA’s green

[Noteable]

December 2023 - The Federal Trade Commission (FTC) scuttles Sanofi’s small molecule licensing deal with Maze Therapeutic - further pointing to the Federal Government's expicit intent to boost biological drug development and commercilization through the IRA. https://www.fiercebiotech.com/biotech/sanofi-scraps-maze-deal-after-ftc-throws-antitrust-obstacles

[Noteable]

As previously posted ...and reinforced by the Ropes & Gray report  ..."Single-indication, rare disease assets are unlikely to be subject to IRA price negotiations, and therefore have attracted the interest of dealmakers." Furthermore, Merck's CEO (MSD and the makers of the the immune checkpoint inhibitor Keytruda) stated earlier this year that MSD's M&A "

[Noteable]

March 11, 2024 - Pfizer’s cancer drugs in mid-stage development are still to show pivotal clinical trial data and become less risky.  Pfizer also highlighted a huge shift in its drug pipeline strategy.  Pfizer's CEO Chriss Boshoff said the oncology division plans to shift to biologic drugs as its main source of revenue, increasing the proportion of those treatments in its

[Noteable]

March 12, 2024 - Merck & Co. (MSD) has signed up the decades-old, pre-clinical, start-up company Pearl Bio’s synthetic biology platform, offering up to $1 billion in biobucks for potential cancer biologics. The hook-up was for Pearl Bio's number of broad-blocking patents giving Pearl the exclusive right to encode synthetic amino acids using engineered synthetases and

[Noteable]

Pearl Bio's whiteboards ideas have been developed over 15 years.  Pearl is pioneering a new era of biotherapeutic design by seeking enabling access to potential new disease targets and the putative evolution of entirely new classes of molecules.  Today MSD has announced it has decided to invest US$1 Billion in this start-up pseud0-biologicis company.

[Noteable]

The IRA’s favorable position is on new large-molecule biologics compared to small-molecule drugs. Provisions allow the former 13 years of immunity from mandated price negotiations, while setting a nine-year exemption period for the latter. “It’s likely to tilt the M&A surge toward large-molecule drugs. What that could translate to is a very real strategic shift in pipelines toward biologics,”

[Noteable]

Thermo Fisher Scientific will divest its anatomical pathology business for $1.1 billion to PHC Holdings. The sale leaves Thermo Fisher in a competitive M&A position among bioprocessing peers, says an analyst.

[Noteable]

April 29, 2024 - Novartis US$2.9 Billion acquisition of MorphoSys in February 2024 involving pelabresib, an investigational small molecule blocker of BET proteins, has run into complications due to safety issues, notwithstanding that at the time of the acquisition announcement it was stated that pelabresib could be a “potentially practice changing treatment option” with an overall favorable

[Noteable]

In September 2023, Abbvie terminated its relationship with I-Mab to develop a cancer drug. https://www.reuters.com/markets/deals/abbvie-terminates-deal-with-i-mab-develop-cancer-drug-2023-09-22/

[Noteable]

https://www.biospace.com/article/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules/

[Noteable]

IIn its most recent edition of its Global Use of Medicines Report, the IQVIA Institute for Human Data Science predicted that losses for originator products will rise from $111 billion to $192 billion by the end of 2028, due to the drug patent cliff and loss of market exclusivity on approved drugs coming off patent. QVIA broke down some of the big trends to watch over the next 5 years:  

[Noteable]

China and India have become small molecule (active pharmaceutical ingredients) (API) manufacturing powerhouses. China manufactures bulk ingredients, which India imports, and then manufactures into oral tablets for export to over 200+ countries and historically sold by Big Pharma companies. This powerhouse combination has geo-political consequences involving security of supply for the United States

[Noteable]

The pharmaceutical product industry is India's most advantageous industry, and it is also an industry with which India hoped to strengthen cooperation with China. In the context of “One Belt, One Road,” China–India pharmaceutical industry cooperation sought to gain global dominance over the pharmaceutical industry, and in so doing, take control of the drug therapeutics industry in the

[Noteable]

The history of the global dependence on Chinese pharmaceuticals is closely linked to the reorganization of the Indian pharmaceutical industry in the 1990s.  India’s participation in the WTO forced the pharmaceutical industry to adopt product patent regulation in line with global standards. Lost to China amongst the reshuffling of the Indian pharmaceutical industry as it partnered and competed

[Noteable]

While the first set of drugs subject to price negotiations are not biomarker-informed agents or advanced cell therapies, many of the companies with drugs on the list — Janssen, Bristol Myers Squibb, Novartis, AstraZeneca, and Merck — also happen to be the biggest players in the oncology space. One year after the Inflation Reduction Act into law, the US Centers for Medicare & Medicaid Services

[Noteable]

Measures are being taken by the EU to reduce their dependency on Chinese for small molecules (synthetic APIs and raw materials), and is taking strategic steps towards self-reliance after the US- China trade war and the Covid-19 outbreak. https://www.beroeinc.com/whitepaper/china-current-state-small-molecule-synthetic-api-market/#:~:text=The%20small%2Dmolecule%20synthetic%20API,the

[Noteable]

Chinese and Indian biomanufacturing executives recognize they lack capabilities required to participate globally.  In contrast to the successes in generic drug production, similar achievements for novel and biosimilar biotherapeutic products have yet to be realized due to a couple of major reasons: (i) these biotherapeutics, particularly monoclonal antibodies, are challenging to manufacture,

[Noteable]

The Indian pharmaceutical industry is generally risk-averse and Indian innovative research has a high risk of failure.

[Noteable]

April 05, 2024 - The French Big Pharma company Sanofi has announced a "restructuring" to move the company into the biologics space which would move the company towards being in concert with the IRA.  According to an internal memo Sanofi's ambitions are to build “an immunoscience powerhouse, set to accelerate launches and transform the practice of medicine” statog that

[Noteable]

April 11, 2024 - " Several factors have contributed to the rise of biotech acquisitions in the pharmaceutical industry. One significant factor is the growing complexity of drug development, particularly in areas such as oncology and rare diseases, where targeted therapies and personalized medicine are becoming increasingly prevalent. Biotech companies, often specializing in these areas

[Noteable]

https://www.biospace.com/article/drug-companies-vcs-rethink-r-and-d-strategies-as-ira-stands-strong-in-court/

[Noteable]

May 06, 2024 -  Bank of America Corp. and BNP Paribas SA are on the verge of winning lead roles arranging US$20 Billion Sanofi’s separation of its consumer-health business. https://www.bnnbloomberg.ca/bofa-bnp-poised-to-win-lead-roles-on-20-billion-sanofi-spinoff-1.2069321

[Noteable]

May 08, 2024 - A glance at the 2023 and early 2024 life science dealmaking environment shows fewer, but higher-value, transactions. Life science companies are demonstrating their willingness to splash out to build portfolio depth in key areas but remain selective about their partnership decisions in the wake of uncertainty around the impending patent cliff, globally high interest rates

[Noteable]

June 20, 2024 - "“As dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in large-scale transformative M&A,” Roel Van den Akker, PwC’s Pharma and Life Sciences Seals Lead, said https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36097745

[Noteable]

https://stockhouse.com/companies/bullboard?symbol=t.onc&postid=36097745

[Noteable]

June  2024 - For the past 2–3 years, biotechnology investors and large pharmaceutical companies alike have been keen to buy late-stage assets—drug candidates that have already been tested in humans, which minimizes the amount of risk a buyer would take on. If decision-makers at the 2024 BIO International Convention in San Diego are to be believed, that’s about to change

[Noteable]

I have sufficiently described the significance of the passing of the IRA and the changes in international regulations in favor of ONCY and ONCY's biologic platform drug pelareorep, which has been granted Orphan/Rare drug status and has been trialed in diseases with 'unment treatment needs'', such as PDAC and mBC. I have described these advantages in detail, yet I have now come to

[Noteable]

An important provision of the IRA is that biological drugs are given 13 years of market exclusivity (protection) versus 9 years of market exclusivity for small molecules. Biologics are large molecule  "living drugs' while small molecules are chemically derived compunds (pills) with an active pharmaceutical ingredient. (API). Active pharmaceutical ingredients (APIs) are the

[Noteable]

Small molecule drugs have well-defined chemical structures, as they are compounds that are manufactured through chemical synthesis. These drugs are typically either synthesized from or meant to replicate natural compounds produced by plants, fungi, and bacteria.  Biologic drugs are extracted from, semi-synthesized by, or manufactured in living organisms using recombinant DNA technology, as

[Jf4270393]

Thank you Noteable for your knowledge and informative information. I am not sure of your background, you allways presnt new material. Cheers!!

[ENEMENEMYNEMO]

Seriously??? He adds no more to this board than I do.   Google "Immune"...cut 'n paste...repeat.  I'd rather read Canfans manifestos. 

[Peladawn]

Hmmm, Lets see..Notable adds vast amounts of pertinent info and technical knowledge, on a daily basis, and you add lies, insults and disruption.. Im pretty sure Id have to say notable adds more to this boardreal close though.

[Buckhenry]

I think the pumpers definition of pertinent  is not pertinent!!!

[Azzak34]

Who are you talking to when you post? It's almost like your referencing us "pumpers" to someone else.  I think we should all start calling you and the other simpletons the "dumpers". Several meanings to the dumpers and they're all pretty apt. 

[ENEMENEMYNEMO]

The term Pumpers too... which I'm sure you're waiting for your mom to go get your pop tarts before you start. 

[Azzak34]

Booooo! You already did the mom pop tarts one. I don't get the connection, unless you're implying some sort of incestuous relationship between me, my mother and pop tarts!?! 

[ENEMENEMYNEMO]

Send pics!

[Azzak34]

Wait, that was what you were getting at? That kind of carry on is illegal where I'm from, I suspect where you're from too.  Isn't coercing someone to commit a crime, in itself a crime? 

[ENEMENEMYNEMO]

You sound guilty...

[Azzak34]

It's 2024 amd you're doing mom jokes? I think on a biotech stock board we can dispense with that kind of humor. So why don't we get off moms? I just got off yours. 

[ENEMENEMYNEMO]

Beat me to that one...she probably would be up for it though. 

[ENEMENEMYNEMO]

...if she were alive...

[Azzak34]

Don't be upset about it, you have a disadvantages you're having to overcome! Ah well that's no good, what happened? 

[Buckhenry]

I think this discussion is much more "pertinent " than the usual  and paste posts ....

[Azzak34]

Again Buckster that's why you're never going to get any smarter. Against all odds you manage to stay suspended in stupid stasis despite the dirth of info posted here almost daily.  Take a few days off from here and educate yourself a bit. Come back to us with your findings. I'll bring the crayons. 

[Buckhenry]

I prefer the box of 64 crayons... they only gave azzak the box of 8 cause he kept eating them. But he has finally graduated to the first grade after 3 attempts at kindergarten... he got to big to fit in the desk. 

[Azzak34]

Way to take my joke and make it unfunnier you silly Dumper.  "Too" big. To big doesn't make sense.  Weren't you threatening to double down on your buffoonery Buck? I haven't noticed a significant uptick in the moron stakes, just the standard level we're all used "to". 

[Buckhenry]

Azzak just don't get it. You could block and never see our post but you choose to respond idiotcally and then we just have fun at your expense. Since we seem to be in a loooong wait and see here there is really nothing new to say on this stock so we make fun of you in the interim. 

[Azzak34]

Are you kidding? I wouldn't miss this for the world! I guess you're not keeping score thougj because I've been destroying you and the other clampets for ages. Go on Stocktwits and bring those clowns here too, you need reinforcements and I need a fresh challenge.  The amount of info posted on here is a crash course on Biotech and Oncology. You and the Dumpers are immune to

[ENEMENEMYNEMO]

That made me laugh. Blood Type D-

[Noteable]

It's uprising how few here understand that the IRA passed in 2022 gives a biologic, like ONCY's pelareorep, 13 years of market exclusivity from the date of FDA product approval. -  REGARDLESS OF PATENT STATUS. ONCY's pelareorep is a "platform drug therapy" that can be used in multiple cancers, most currently in pancreatic, breast, anal, and colon cancer, with the

[Noteable]

Should readf: '...ONCY would likely choose the "Orphan Drug"  Accelerated Approval pathway for pelareorep in the pancreatic cancer indications..." and the "unmet treatment need" Accelerated Approval pathway for the rest of the indictions that pelareorep would seek approval in. 

[Noteable]

On September 12, 2022, President Biden signed an Executive Order (E.O.) on “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy.” In the E.O., the President laid out his vision for a whole-of-government approach to advance biotechnology and biomanufacturing by creating a research agenda that outlines the foundational and use-inspired R

[Noteable]

While traditional forms of manufacturing therapeutics, such as small molecules, biologics, peptides, and cell-based therapies, can be considered sufficient to meet the demands of patients with common diseases, certain cases require new ways to produce therapeutics quickly and at a large scale, such as occurred during the recent COVID-19 pandemic, new capabilities are being developed to meet the

[Noteable]

ONCY's novel scalable, flexible and reliable biomanufacturing patent for pelareorep is effective until at least 2031, after which further biomanufacturing patent extensions can be applied and become effective. 

[Noteable]

The rising prominance of the IRA and the shift towards biologic drug therapies (biopharmaceuticals) over the last few years, are two key trends that will have a lasting impact on the small molecule segment : China + 1 strategy: India is currently the second largest CDMO player globally, after China, for small molecules. India’s market significance has grown markedly over the last three

[Noteable]

March 19, 2024 - The passing of the BIOSECURE Act could deal a devastating blow to  China based WuXi AppTec’s business. For one, the company would be cut off from the possibility of U.S. contracts or grants fueled by taxpayer dollars. But, more critically, the proposed law would forbid the federal government from contracting with other drugmakers who work with one of the aforementioned

[Noteable]

MARCH 18, 2024 -  The BIOSECURE Act: Proposed New Legislation Could Affect U.S. Companies’ Plans to Contract With Chinese Biotechnology Companies - By James C. Shehan and Daniel C. Porco " The Biosecure Act would prohibit all executive agencies from contracting with or extending loans or grants to any company with current or future commercial arrangements

[Noteable]

As for the rationale behind the Biosecure Act, the Act’s preamble states that China’s military has invested in biotech and AI capabilities and, through control of Chinese businesses, has access to millions of Americans’ genetic data. Thus, the Act is intended to stop taxpayer money from funding foreign adversaries’ hostile actions and to stop the flow of genomic data of Americans to the Chinese

[Noteable]

March 06, 2024 - Ropes & Gray insight alert on the Biosecure Act. Senate Committee Votes to Send the BIOSECURE Act to the Senate Floor March 6, 2024 https://www.ropesgray.com/en/insights/alerts/2024/03/senate-committee-votes-to-send-the-biosecure-act-to-the-senate-floor Plus: New Executive Order Would Restrict Transfer of Certain Bulk Sensitive Personal Data and United States

[Noteable]

The Biosecure Act provides that : " ....  the restrictions would also apply to any entity owned by, controlled by, or subject to the jurisdiction or direction of a country of concern as well as any person “knowingly causing or directing, directly or indirectly, a violation” of the regulations."

[Noteable]

 .... so goodbye to Andrew de G.

[Noteable]

On February 02, 2024 the proposed BIOSECURES ACT (Biosecurity Act) was announced in the US Senate which caused the immediate sell-off of Chinese biotech companies, including WuXi AppTec, BGI Group MGI and Complete Genomics. On February 06, 2024 approximately 3.74 million shares of ONCY were sold on the NASDAQ and approximately 675K on the TSX,  followed by another 1.75 million

[Noteable]

Should read : " On February 06, & February 07, 2024 a combined total of approximately 3.74 million shares of ONCY were sold on the NASDAQ and approximately 675K on the TSX ..." 

[Noteable]

" On February 06, & February 07, 2024 a combined total of approximately 3.74 million shares of ONCY were sold on the NASDAQ and approximately 675K on the TSX ..."  On February 08, 2024 this happened ... https://www.reuters.com/markets/deals/trumps-media-deal-partner-nears-50-million-financing-sources-2024-02-08/

[Noteable]

Goldman Sachs 45th Annual Healthare Conference - June 10-13, 2024 - Pfizer's CEO Albert Bourla further commits to Pfizer's March 2024 decision to focus on biologics, and not small molecules, as a consequence of the IRA and the 13 years of exclusivity provided to novel biologic drugs versus 9 years for small molecules.In 5 years Pfizer's oncology portfolio will be comprised of 60-65

[Noteable]

“Biologics represent a more durable revenue potential based on a number of factors, including differentiated access and affordability to the patient, IRA considerations and patent expiration timeline,” according to Suneet Varma, commercial president of Pfizer Oncology. Pfizer’s messaging to investors is that the company is shifting toward a “more balanced portfolio mix,” Varma said, which will be

[Noteable]

May 14, 2024 - Recent Trends in the Global Cancer Biologics Market In recent years, the global cancer biologics market has witnessed several notable trends that have reshaped its dynamics: Rise of Targeted Therapies: Targeted therapies have emerged as a significant driver of demand in the global cancer biologics market. These therapies, designed to specifically interfere with the

[canadafan]

Nice capulation of the upcoming & changing trends in cancer care. Oncolytics biotech, fit into 4 of the 4, categories. Yes Onc has been around 20+ years. however the technology & science to support the co- therapeutic use, is certainly on the upswing. Utilizing & understanding the 4 points  Targeted therapy, precision medicine, oncokytics viruses, liquid biopsies. All in some form

[Noteable]

        Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  

[Noteable]

May 14, 2024 - Recent Trends in the Global Cancer Biologics Market In recent years, the global cancer biologics market has witnessed several notable trends that have reshaped its dynamics: Rise of Targeted Therapies: Targeted therapies have emerged as a significant driver of demand in the global cancer biologics market. These therapies, designed to specifically interfere with the

[Peladawn]

lol....an article from New York Magazine!....the leftist of the left.... ...."Steele Dossier was 'Case Study' in Journalistic Manipulation"..... https://nymag.com/intelligencer/2021/07/steele-dossier-was-case-study-in-journalistic-manipulation.html

[Noteable]

Thr IRA was developed and introduced in January 2022 under the current US administration to protect the drug development and innovation system from the small molecule industry that is predominately located in China and India. Such recently passed Acts were introduced to heightened the US global competitive advantages which were eroded under the previous administration. By doing so the US is

[Noteable]

In FY 2023 total government deficit was reduced to US $1.70 Trillion.

[Noteable]

For example, while the Trump administration was working to erode a rules based society, just this past Thursday the European Commission accused India-based pharma company Alchem International of taking part in a “long-lasting cartel” to fix the minimum price of a widely used pharmaceutical ingredient. This regulatory action emphasizes the need to protect the best interest of the common

[Noteable]

April 2024 - https://www.bloomberg.com/news/articles/2024-04-25/us-says-china-moving-too-slowly-on-protecting-intellectual-property

[Noteable]

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-inc?postid=36090531

[Noteable]

June 10, 2024 - The global cancer immunotherapy market size was estimated at USD 126.19 billion in 2023 and is projected to hit around USD 296.01 billion by 2033, growing at a CAGR of 8.9% during the forecast period from 2024 to 2033. North America dominated the market with the largest revenue share of 45.11% in 2023 . - Oncolytic Viral Therapies and Cancer Vaccines is